Authors: Cadegiani FA PMID: 35971401 PMCID: PMC9372380 DOI: 10.7759/cureus.27883 Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine-induced myocarditis is a rare but well-documented complication in young males. The increased incidence of sudden death among athletes following vaccination has been reported and requires further investigation. Whether the risk of myocarditis, [...]

Authors: Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA PMID: 35436552 PMCID: PMC9012513 DOI: 10.1016/j.fct.2022.113008 Abstract The mRNA SARS-CoV-2 vaccines were brought to market in response to the public health crises of Covid-19. The utilization of mRNA vaccines in the context of infectious disease has no precedent. The many alterations in the vaccine mRNA hide [...]

Auhtors: Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA PMID: 35436552 PMCID: PMC9012513 DOI: 10.1016/j.fct.2022.113008 Abstract The mRNA SARS-CoV-2 vaccines were brought to market in response to the public health crises of Covid-19. The utilization of mRNA vaccines in the context of infectious disease has no precedent. The many alterations in the vaccine mRNA hide [...]

Authors: Schauer J, Buddhe S, Gulhane A, Sagiv E PMID: 35351530 PMCID: PMC8957353 DOI: 10.1016/j.jpeds.2022.03.032 Abstract We describe the evolution of cardiac magnetic resonance imaging findings in 16 patients, aged 12-17 years, with myopericarditis after the second dose of the Pfizer mRNA coronavirus disease 2019 vaccine. Although all patients showed rapid clinical improvement, many had [...]

Authors: Chen BM, Cheng TL, Roffler SR PMID: 34469112 DOI: 10.1021/acsnano.1c05922 Abstract Polyethylene glycol (PEG) is a flexible, hydrophilic simple polymer that is physically attached to peptides, proteins, nucleic acids, liposomes, and nanoparticles to reduce renal clearance, block antibody and protein binding sites, and enhance the half-life and efficacy of therapeutic molecules. Some naïve individuals [...]

Authors: Verma AK, Lavine KJ, Lin CY PMID: 34407340 PMCID: PMC8385564 DOI: 10.1056/NEJMc2109975 Abstract The Centers for Disease Control and Prevention recently reported cases of myocarditis and pericarditis in the United States after coronavirus disease 2019 (Covid-19) messenger RNA (mRNA) vaccination.1 In recently published reports, diagnosis of myocarditis was made with the use of noninvasive [...]

Authors: Seneff S, Nigh G AbstractOperation Warp Speed brought to market in the United States two mRNA vaccines, produced by Pfizer and Moderna. Interim data suggested high efficacy for both of these vaccines, which helped legitimize Emergency Use Authorization (EUA) by the FDA. However, the exceptionally rapid movement of these vaccines through controlled trials [...]

Authors: Blumenthal KG, Robinson LB, Camargo CA, Shenoy ES, Banerji A, Landman AB PMID: 33683290 PMCID: PMC7941251 doi:10.1001/jama.2021.3976 Abstract Anaphylaxis to the mRNA COVID-19 vaccines is currently estimated to occur in 2.5 to 11.1 cases per 1 million doses, largely in individuals with a history of allergy.1 Allergic concerns contribute to vaccine hesitancy; we [...]